These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28622413)

  • 1. Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Shear NH; Alhusayen R; Fernandez-Obregon A; Kimball AB; Menter A; Wu JJ; Goyal K; Patel H; Lin R; Armstrong AW
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e544-e547. PubMed ID: 28622413
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Menter A; Papp KA; Gooderham M; Pariser DM; Augustin M; Kerdel FA; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Chavers S; Naessens D; Sermon J; Krueger GG
    J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1148-58. PubMed ID: 27027388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kimball AB; Guenther L; Kalia S; de Jong EMGJ; Lafferty KP; Chen DY; Langholff W; Shear NH
    JAMA Dermatol; 2021 Mar; 157(3):301-306. PubMed ID: 33533924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
    Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
    J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).
    Kimball AB; Leonardi C; Stahle M; Gulliver W; Chevrier M; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Menter A;
    Br J Dermatol; 2014 Jul; 171(1):137-47. PubMed ID: 24684204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical eye on registry data in psoriasis.
    Egeberg A; Nast A
    Br J Dermatol; 2017 Jul; 177(1):245-246. PubMed ID: 28731238
    [No Abstract]   [Full Text] [Related]  

  • 8. The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry.
    van den Reek JMPA; Seyger MMB; van Lümig PPM; Driessen RJB; Schalkwijk CJM; Berends MAM; van de Kerkhof PCM; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):615-623. PubMed ID: 29121430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
    J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    deShazo R; Soltani-Arabshahi R; Krishnasamy S; Langley RG; Kalia S; Ståhle M; Langholff W; Goyal K; Fakharzadeh S; Galindo C; Srivastava B; Krueger G
    J Drugs Dermatol; 2019 Oct; 18(10):1059-1060. PubMed ID: 31603636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographic Variations in Biologic Therapy and Disease Characteristics: A Pilot-Study in the Corrona Psoriasis Registry.
    Enos CW; O'Connell KA; Harrison RW; McLean RR; Dude B; Van Voorhees AS
    J Drugs Dermatol; 2020 Nov; 19(11):1119-1122. PubMed ID: 33196741
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis.
    Langley RG; Poulin Y; Srivastava B; Lafferty KP; Fakharzadeh S; Langholff W; Augustin M
    J Am Acad Dermatol; 2021 Jan; 84(1):60-69. PubMed ID: 32798580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Side effects of biologic therapies in psoriasis].
    Altenburg A; Augustin M; Zouboulis CC
    Hautarzt; 2018 Apr; 69(4):290-297. PubMed ID: 29568996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposal for long-term protocols after Psoriasis Area and Severity Index clear with initial biologic therapy: Happily ever after with or without biologics in psoriasis therapy.
    Sano S
    J Dermatol; 2017 Oct; 44(10):e234-e235. PubMed ID: 28623843
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
    Fiorentino D; Ho V; Lebwohl MG; Leite L; Hopkins L; Galindo C; Goyal K; Langholff W; Fakharzadeh S; Srivastava B; Langley RG
    J Am Acad Dermatol; 2017 Nov; 77(5):845-854.e5. PubMed ID: 28893407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Strober B; Gooderham M; de Jong EMGJ; Kimball AB; Langley RG; Lakdawala N; Goyal K; Lawson F; Langholff W; Hopkins L; Fakharzadeh S; Srivastava B; Menter A
    J Am Acad Dermatol; 2018 Jan; 78(1):70-80. PubMed ID: 29102053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why Biologic Therapies Sometimes Lose Efficacy.
    Strober BE
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S78-80. PubMed ID: 27525443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with successful switching between biologic therapies for the treatment of psoriasis in daily dermatological real-life practice: The Resoswitch study.
    Dabouz F; Khemis A; Barbe C; Lahfa M; Maccari F; Chaby G; Beneton N; Boye T; Esteve E; Mahé E; Begon E; Pauwels C; Bernard P; Taieb C; Reguiai Z;
    Dermatol Ther; 2019 Mar; 32(2):e12789. PubMed ID: 30488520
    [No Abstract]   [Full Text] [Related]  

  • 20. Combining biologics with methotrexate in psoriasis: a systematic review.
    van Bezooijen JS; Prens EP; Pradeepti MS; Atiqi R; Schreurs MWJ; Koch BCP; van Gelder T; van Doorn MBA
    Br J Dermatol; 2015 Jun; 172(6):1676-1680. PubMed ID: 25470815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.